FDG uptake, a surrogate of tumour hypoxia? by Dierckx, Rudi & Van De Wiele, Christophe
REVIEW ARTICLE
FDG uptake, a surrogate of tumour hypoxia?
Rudi Andre Dierckx & Christophe Van de Wiele
Received: 23 October 2007 /Accepted: 18 February 2008 / Published online: 29 May 2008
# The Author(s) 2008
Abstract
Introduction Tumour hyperglycolysis is driven by activa-
tion of hypoxia-inducible factor-1 (HIF-1) through tumour
hypoxia. Accordingly, the degree of 2-fluro-2-deoxy-D-
glucose (FDG) uptake by tumours might indirectly reflect
the level of hypoxia, obviating the need for more specific
radiopharmaceuticals for hypoxia imaging.
Discussion In this paper, available data on the relationship
between hypoxia and FDG uptake by tumour tissue in vitro
and in vivo are reviewed. In pre-clinical in vitro studies,
acute hypoxia was consistently shown to increase FDG
uptake by normal and tumour cells within a couple of hours
after onset with mobilisation or modification of glucose
transporters optimising glucose uptake, followed by a delayed
response with increased rates of transcription of GLUT
mRNA. In pre-clinical imaging studies on chronic hypoxia
that compared FDG uptake by tumours grown in rat or mice to
uptake by FMISO, the pattern of normoxic and hypoxic
regions within the human tumour xenografts, as imaged by
FMISO, largely correlated with glucose metabolism although
minor locoregional differences could not be excluded. In the
clinical setting, data are limited and discordant.
Conclusion Further evaluation of FDG uptake by various
tumour types in relation to intrinsic and bioreductive
markers of hypoxia and response to radiotherapy or
hypoxia-dependent drugs is needed to fully assess its
application as a marker of hypoxia in the clinical setting.
Keywords FDG PET. Hypoxia
Introduction
The most important non-surgical treatment for cancer is
radiotherapy; of the 50% of cancer patients that can be
currently cured, 70% receive radiation either as monotherapy
or as part of a multimodality treatment. For a number of
tumours such as squamous cell carcinoma of the head and
neck or cervix carcinoma, radiotherapeutic treatment may fail
due to the presence of tumour hypoxia (pO2<5 mmHg) which
decreases the availability of oxygen free radicals that are
necessary to induce sufficient DNA damage to cause cell
death [1–4]. A non-invasive imaging technique allowing the
identification and quantification of hypoxia in these patients
may identify those patients that might benefit from concom-
itant radiosensitisation therapy or from dose escalation.
During the past two decades, several hypoxia-targeting
radiopharmaceuticals have been developed. The chemical
basis for most of these compounds, e.g. 18F-misonidazole
(18F-MISO) and 18F/123I-iodoazomycin arabinoside (18F-
AZA/123I-AZA, respectively), has been to incorporate a
2-nitroimidazole moiety to act as a bioreductive molecule
accepting a single electron and producing a free radical
anion, which, after further reduction, is then incorporated
into cell constituents under hypoxic conditions [5, 6]. For
other non-imidazole moiety containing hypoxia-targeting
radiopharmaceuticals, e.g. 99mTc-2,2′-(1,4-diaminobutane)
bis(2-methyl-3-butanone)dioxime (99mTc-HL91) and 62Cu-
diacetyl-bis(N-4-methylthiosemicarbazone) (62Cu-ATSM),
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the mechanisms of tumour accumulation is not well-
clarified, although it is generally accepted that the 99mTc
and 62Cu complexes are bioreducible groups themselves.
To find routine clinical application, these radiopharmaceut-
icals should be widely available, provide meaningful
averages over tumour volumes and allow for administra-
tion, before, during and after the investigation of tumour
oxygenation and re-oxygenation. Unfortunately, their syn-
thesis, however, requires either the presence of a cyclotron
or specialised in-house radiopharmacy expertise, facilities
still unavailable to most nuclear medicine departments [5,
6]. Contrary to hypoxia-targeting radiopharmaceuticals, 2-
fluro-2-deoxy-D-glucose (FDG) is widely available. The
basis for the application of FDG PET imaging in oncology
is the upregulation of glucose transporters (GLUTs) and
glycolytic enzymes also known as the Warburg effect or
tumour hyperglycolysis [7, 8]. It is important to note that
tumour hyperglycolysis is driven by the activation of
hypoxia-inducible factor-1 (HIF-1) either through genetic
alterations or changes of levels of growth factors and also
via tumour hypoxia. Accordingly, the degree of FDG
uptake by tumours might indirectly reflect the level of
hypoxia, obviating the need for more specific radiopharma-
ceuticals for hypoxia imaging. This paper reviews available
data on the relationship between hypoxia and FDG uptake
by tumour tissue in vitro and in vivo.
Pre-clinical findings
Cell line findings
The uptake of 3H-FDG into two human tumour cell lines
(HTB 63 melanoma and HTB 77 IP3 ovarian carcinoma)
was determined after exposure to differing oxygen atmos-
pheres ranging from 0% to 20% O2 for varying time
periods by Clavo et al. [9]. FDG uptake in both melanoma
and ovarian carcinoma cell lines increased significantly
(39.6±6.7% and 36.7±9%, respectively) over basal (20%
O2) conditions when cells were exposed to a mild hypoxic
environment (5% O2) for 1.5 h. With a 4-h exposure to
1.5% O2, the increase in FDG uptake was greater at 52.3±
8.9% and 43.5±19%, respectively. With 4 h of anoxia, the
increase in FDG uptake over basal conditions was 42.7±10%
and 63.3±13.7% for melanoma and ovarian carcinoma cells,
respectively. Membrane transport of 3-O-methylglucose
(3-OMG) was increased by hypoxia for melanoma and
ovarian carcinoma. Immunochemical assays for Glut-1
showed an increase in the membrane expression of the
Glut-1 transporter in cells exposed to hypoxia.
Hypoxic accumulation of 2-[5,6-3H]fluoro-2-deoxy-D-
glucose was evaluated in two cell lines (UT-SCC-5 and UT-
SCC-20) obtained from patients with squamous cell
carcinoma of the head and neck by Minn et al. [10]. Both
cell lines were exposed to decreasing oxygen atmosphere
(20%, 1.5%, or 0% O2) for 6 h, after which they were
incubated for a further 1 h with tritiated FDG. An anoxic
atmosphere resulted in a mean increase of 3H-FDG uptake
of 120% and 46% over a baseline 20% oxygen atmosphere
for UT-SCC-5 and UT-SCC-20A, respectively.
Similarly, a more than twofold increase (2.53±0.79; p<
0.005) in 3H-FDG uptake was observed under hypoxic
conditions by Burgman et al. by MCF-7 breast cancer cells,
but no changes in the cellular levels of glucose transporter
proteins (GLUT1 and GLUT3) or hexokinase were ob-
served [11]. A reducing agent, dithiothreitol (DTT), also
caused an increase in 3H-FDG uptake but failed to affect
uptake under hypoxic conditions. This indicates that the
mechanisms by which hypoxia and DTT affect 3H-FDG
uptake might be the same. The oxidising agent chloromer-
curibenzenesulphonic acid (pCMBS) had no effect on 3H-
FDG uptake under normoxic conditions but counteracted
the effect of hypoxia. DTT caused an increase in glucose
transporter activity, whereas it had no effect on hexokinase
activity. pCMBS had no effect on either glucose transporter
activity or hexokinase activity. The authors concluded that
hypoxia-induced increase in 3H-FDG uptake in MCF7 cells
is the result, in part, of an increase in glucose transporter
activity resulting from the modification (reduction) of thiol
group(s) in the glucose transport protein(s) and that the
modulation of hexokinase activity is probably not involved
in the hypoxia-induced increase in 3H-FDG uptake in these
cells.
Pedersen et al. studied the relationship between 18F-
labelled FDG uptake and expression of glucose transporters
(GLUTs 1, 2 and 3) in two human small cell lung cancer
(SCLC) lines CPH 54A and CPH 54B [12]. Changes in the
expression of GLUTs and vascular endothelial growth
factor (VEGF) during 12, 18, and 24 h of severe hypoxia
in vivo (xenografts) and in vitro (cell cultures) were
recorded for both tumour lines. There were higher levels
of Glut-1 protein in 54B and a correspondingly higher FDG
uptake in this tumour line (p<0.001). During hypoxia, a
significant upregulation of VEGF mRNA, GLUT-1 mRNA
and Glut-1 and Glut-3 proteins occurred with a distinctly
different time course in the two cell lines. A similar co-
upregulation of GLUT and VEGF was seen in hypoxic
tumours of both lines. There were no significant changes of
HIF-1alpha mRNA during hypoxia in either of the cell
lines.
Hara et al. monitored the uptake of [18F] 2-fluoro-2-
deoxyglucose (18F-FDG) in androgen-independent PC-3
cells and androgen-sensitive LNCaP cells under aerobic or
anoxic conditions [13]. The effect of androgen depletion
was also examined. After 4 h of anoxia, PC-3 cells showed
an 85% increase in FDG uptake whereas LNCaP cells
showed a 212% increase in FDG uptake. Of interest,
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androgen depletion resulted in a marked decrease in the
uptake of 18F-FDG in LNCaP cells but not in PC-3 cells.
Finally, Oswald et al. studied FDG uptake in three
tumour cell lines, namely, HT-29 (colorectal), FaDu
(SCCHN) and MCF-7 (HT-29 and FaDu) and in three
primary endothelial cell lines cultured at normoxic and
hypoxic conditions [14]. In comparison to normoxic
conditions, cellular uptake of 18F-FDG was significantly
increased at hypoxic conditions in two of the three
tumour cell lines under study and all three endothelial
cell lines.
Animal models
Dearling et al. injected mice (MF1) bearing LS174T human
tumour xenografts premixed 18F-FDG (100 MBq), 14C-
2DG (0.37MBq) and pimonidazole hydrochloride (60mg/kg)
[15]. After 30, 60 and 120 min, tissues (n=4) were taken
and counted for whole-body biodistribution. Tumours were
frozen, sectioned and exposed to phosphor image plates to
obtain a quantitative digital image of radionuclide distri-
bution. Sections were then stained to reveal tumour
pathophysiology. Viable tissues were separated from
necrotic tissues based on haematoxylin and eosin staining
and manually based on regions of interest. Within these
regions, the amount of hypoxic (brown staining or
pimonidazole-positive) and normoxic tissue (blue staining
or pimonidazole-negative) was assessed using an automated
colour-discriminating in-house written software programme.
Whole-body biodistributions and tumour microdistribution
for the tracers were similar (r=0.85±0.10, p<0.0001 for
tumour uptake). When the tumours were divided into viable
and necrotic regions, the ratio of mean counts per pixel was
1.96 (p<0.0001), whereas for hypoxic versus normoxic
regions, it was 1.26 (p<0.0001). There was no significant
difference in selectivity for hypoxia between the tracers (p=
0.86). This study confirmed the selectivity of deoxyglucose
for viable cells over necrotic regions and for hypoxic cells
over normoxic regions in vivo.
FDG PET and 18F-FMISO PET imaging was performed
with a dedicated small-animal PET scanner NanoPET
(Oxford Positron Systems) in ten different human tumour
xenografts in nude mice and B16 melanoma tumours in
syngeneic Balb/c mice by Wyss et al. The pattern of
normoxic and hypoxic regions within the human tumour
xenografts, as imaged by 18F-FMISO and 18F-FDG proved
similar. In addition, the uptake values of FDG and
parameters used to quantify FMISO accumulation exhibited
a strong positive correlation [16].
Zanzonico et al. studied the intra-tumoural distributions
of sequentially administered F18-fluoro-deoxyglucose
(FDG) and the hypoxia tracer 18F-fluoromisonidazole
(FMISO) were compared in nude rats with a hindlimb
R3327-AT anaplastic rat prostate tumour xenograft and a
hindlimb FaDu human squamous cell carcinoma (each up
to 20×20×30 mm in size) rats by registered micro-PET
imaging with positioning of each animal in a custom-
fabricated whole-body mould [17]. The registered micro-
PET images unambiguously demonstrated grossly similar
although not identical distributions of FDG and FMISO in
the tumours—a high-activity rim surrounding a lower-
activity core. There were, however, subtle but possibly
significant differences in the intra-tumoural distributions of
FDG and FMISO.
Tanaka et al. studied the intra-tumoural distribution of
64Cu-diacetyl-bis(N4-methylthiosemicarbazone) ([64Cu]Cu-
ATSM) and 18F-FDG in mice with tumours of four different
origins (LLC1, Meth-A, B16 and colon26) compared to
immunohistochemical staining of proliferating cells
(Ki67), blood vessels (CD34 or von Willebrand factor),
and apoptotic cells (terminal deoxynucleotidyltransferase-
mediated dUTP nick end labelling method) [18]. With all
cell lines, [64Cu]Cu-ATSM and 18F-FDG were distributed
with different gradation in the tumour mass. The immuno-
histochemical study suggested that the high [64Cu]Cu-
ATSM uptake regions were hypovascular and consisted of
tumour cells arrested in the cell cycle, whereas the high
18F-FDG uptake regions were hypervascular and consisted
of proliferating cells.
Clinical findings
Squamous cell carcinoma of the head and neck (SCCHN)
Zimny et al. studied 24 patients suffering from SCCHN
with metastatic lymph nodes that underwent FDG PET,
FMISO PET and pO2-polarography within 1 week [19].
Parameters of pO2-polarography were the relative frequency
of pO2 readings ≤2.5, ≤5 and ≤10 mmHg, respectively, and
the mean and median pO2 in lymph nodes under study.
Whilst a moderate correlation of the maximum standardised
uptake value (SUVmax) of FDG with the tumour and/or
lymph node to blood ratio of FMISO at 2 h (r=0.53, p<
0.05) was observed, SUV of FDG was similar in hypoxic
and normoxic tumours as defined by pO2-polarography
(6.9±3.2 vs 6.2±3.0, NS) and the FDG uptake was not
correlated with the results of pO2-polarography whereas
FMISO uptake was (r=0.80, p<0.001) [19]. These results
were later on confirmed by the same authors in an extended
series of 36 patients [20].
Thorwarth et al. studied 12 patients suffering from
advanced head and neck cancer (HNC) that underwent
FDG and FMISO PET examinations before RT treatment.
In this series, tumour volume was defined in two steps; first
through region growing, using a threshold of 60% of the
maximum FDG uptake value followed by an extension of
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this volume by 3 voxels in each direction yielding the final
tumour volume [21]. The percentage of voxels of each
tumour that presented FMISO SUV values at 2 h pi. larger
than 1.4 defined the hypoxic fraction of each tumour. The
authors also performed a scatter-plot based voxel-by-voxel
FDG–FMISO correlation for each patient for the defined
tumour volumes and assessed whether the slope of the
regression line (m) and the scatter width of the scatter plots
(sigma) allowed to stratify the patient group with respect to
treatment outcome. No general correlation of enhanced
glucose metabolism and FMISO uptake was observed. In
seven out of the 12 patients studied, scatter patterns for the
primary tumour were very narrow suggesting a functional
dependence of FDG and FMISO uptake. In the two patients
in whom lymph nodes were also included for analysis,
widely dispersed data points of FDG and FMISO SUVs
were found for lymph nodes. Finally, whereas the maxi-
mum uptake of FMISO (p=0.045) showed borderline
significance for stratifying the patient group, FDG positive
tumour volume, hypoxic fraction, maximum FDG uptake
and m were not significant. Sigma turned out to be the most
significant variable (p=0.008) to predict treatment success
probabilities.
In a study by Rajendran et al., the mean correlation
coefficient between FMISO and FDG uptake by primary
SCCHN on a pixel-by-pixel basis per tumour was 0.62
[22]. In this study, patients suffering from different T-stages
were included and FDG uptake by the primary tumour
covered a wide range (FDG SUV max=2.9–25.4).
Non-small cell lung carcinoma (NSCLC)
Cherk et al. prospectively studied 21 patients with suspected
or biopsy-proven NSCLC that underwent both FMISO and
FDG PET [23]. Seventeen patients subsequently underwent
surgery with analysis performed for tumour markers of
angiogenesis and hypoxia. In the 17 patients with resectable
NSCLC (13 men, 4 women; age range=51–77 years), the
mean FMISO uptake in tumour was significantly lower
than that of FDG uptake (p<0.0001) and showed no
correlation with FDG uptake (r=0.26). The hypoxic cell
fraction of primary NSCLC was consistently low, and there
was no significant correlation in NSCLC between hypoxia
and glucose metabolism in NSCLC assessed by 18F-FDG.
Similar findings were obtained by Gagel et al. in a series
of 18 NSCLC patients who also underwent both FMISO
and FDG PET [24].
Finally, Dehdashti et al. performed 60Cu-ATSM and
FDG PET in a series of 19 NSCLC carcinoma patients. In
the 14 patients in whom response to therapy was assessed,
no significant correlation between tumour 60Cu-ATSM
and FDG SUV max values (r=0.04; p=0.9) was found
[25].
Other tumour types
Cher et al. studied 17 patients with suspected primary
glioma with 18F-FMISO and 18F-FDG PET [26]. There was
100% concordance as to the absence or presence of uptake
of both tracers in all tumours under study with five patients
displaying a lack of uptake of either tracer preferentially in
low-grade tumours. The pattern of uptake of both tracers
within positive tumours was, however, different with areas
of marked FMISO uptake often corresponding to areas of
only slightly increased FDG uptake.
Finally, no significant correlation was found between
FDG SUV max values and FMISO SUVmax values in
patients suffering from soft tissue sarcoma, breast cancer or
glioblastoma multiforme (r values, respectively, 0.47, 0.38
and 0.32; number of patients studied, respectively, 11, 7
and 5) [22].
Discussion
Solid tumours consist of regions with large numbers of
hypoxic cells compared with the surrounding normal tissue
with substantial heterogeneity within a given tumour and
among tumours of the same histology [7, 8]. The
underlying process involved in generating a hypoxic
micro-environment is not well-understood but likely in-
clude various mechanisms of impaired intra-tumoural
oxygen delivery and consumption. In particular, tumour
hypoxia seems to arise from the stochastic development of
vasculature during tumour growth. Tumour blood vessels
are highly irregular, lack smooth muscles and innervation,
may have an incomplete endothelial lining and basement
membrane and often develop from post capillary venules,
creating severe longitudinal pO2 gradients within the
vessels themselves. Because of these factors, a significant
proportion of tumour cells lie beyond the diffusion distance
of oxygen, rendering them chronically or diffusion-limited
hypoxic. In addition, tumour hypoxia can also occur
acutely because of transient occlusion, narrowing of
vessels, arteriolar vasomotion and variation in red cell
traffic patterns. Models based on data generated from
experimental studies suggest that substantial volumes of
solid tumours are exposed to cyclic episodes of acute or
transient hypoxia. Both acute and chronic hypoxia are
present at any time in tumour tissues, the latter form
predominating, and their influence on FDG uptake has been
studied by various authors.
In pre-clinical in vitro studies, acute hypoxia was
consistently shown to increase FDG uptake by normal and
tumour cells within a couple of hours after onset [9–13].
The time course and extent of uptake proved very different
from one tumour cell line to another. In addition, in those
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few studies that looked at associated changes in glucose
transporter expression and hexokinase activity, a significant
increase in the number of glucose transporters but not
hexokinase activity was evidenced which may be due to
recycling of internalised receptors to the cell membrane or
to a decreased rate of internalisation of GLUTs. In addition,
in one study by Burgman et al., it was suggested that
modification (reduction) of thiol group(s) present on
GLUTs through hypoxia may increase the kinetics of
glucose transport by GLUTs [11]. In the one study that
performed delayed assessment of glucose uptake after 18–
24 h of acute hypoxia, mRNA analysis was performed
revealing increased levels of mRNA of amongst others
GLUTs and VEGF [12]. Overall, these findings suggest a
rapid onset response of cells to hypoxia with mobilisation
or modification of GLUTs optimising glucose uptake,
followed by a delayed response with increased rates of
transcription of GLUT mRNA.
In pre-clinical imaging studies on chronic hypoxia that
compared FDG uptake by tumours grown in rats or mice to
uptake by FMISO, the pattern of normoxic and hypoxic
regions within the human tumour xenografts, as imaged by
FMISO, largely correlated with glucose metabolism al-
though minor locoregional differences could not be
excluded [16, 17]. This finding suggests a compensatory
mechanism for the reduced delivery of glucose to hypoxic
tumour cells by augmented tissue extraction owing to
elevated glucose transporter activity under hypoxia in the
tumour models under study. As opposed to FMISO, in the
one study that compared 64Cu-ASTM to FDG uptake by
tumour tissues, findings proved discordant [18]. In all four
tumour models under study, LLC1, colon26, Meth-A and
B16, FGD and 64Cu-ATSM were accumulated with
different gradation forming a unique pattern of a high
64Cu-ATSM region surrounding a high FDG region within
a tumour mass which in turn surrounded a necrotic core.
The imaging results obtained with 64Cu-ATSM are at the
least to say surprising and quite opposite to the general
model of tumour hypoxia that includes a peripheral viable
core, a central necrotic core and a hypoxia rim in between.
Contrariwise, the images obtained with FDG proved similar
to those obtained by Dearling et al. who compared
pimonidazole staining with FDG uptake in a MCF-7
tumour model and found similar results for both tracers
[15]. Due to the lack of a gold standard for hypoxia, e.g.
polarography, no definitive conclusions can be derived
from this study.
Data reporting on the relationship between FDG uptake
and tumour hypoxia in the clinical setting are limited. In
patients suffering from squamous cell carcinoma of the
head and neck, studies have looked at the relationship
between hypoxia and FDG uptake in both lymph nodes
(one cumulative series of 36 patients by Gagel et al.) and
primary tumours (two series of patients suffering from
SCCHN, respectively, one on 12 patients by Thorwarth et
al. and one reporting on 38 patients by Rajendran et al.)
with seemingly conflicting results [19–22]. Whereas no
relationship was found between FDG uptake and hypoxia
in lymph nodes and in the smaller study in primary tumours
by Thorwarth et al., a significant relationship was found in
primary tumours in the study by Rajendran et al. [21, 22].
Based on available data, hypoxic regions appear to be
distributed homogeneously in cervical lymph node metas-
tases from SCCHN and there is no gradient of oxygenation,
contrary to what is seen in primary tumours [27]. In
addition, the level of hypoxia is inversely correlated with
lymph node perfusion, suggesting that hypoxia in invaded
lymph nodes is flow-related rather than diffusion-related as
is the case in primary tumours [27]. It is currently unknown
whether the degree of hypoxia is also related to the level of
lymph node involvement or not. The lack of such a
relationship might also explain the lack of a relationship
between hypoxia and FDG accumulation in lymph nodes as
demonstrated in the series by Gagel et al. In the series by
Thorwarth et al., a selective group of patients appears to
have been included based on the narrow range of FDG
SUVmax values (from 7.84 to 12.07; mean=9.53) of the
primary tumour. Within this narrow range, a much larger
cohort of patients is likely required to prove or exclude the
existence of a relationship between FDG and FMISO
uptake. Opposite to the series by Thorwarth et al., in the
study by Rajendran et al. that did find a relationship
between FDG and FMISO accumulation, FDG SUV values
covered a wide range (from 2.9 to 25.4; mean=10.9).
In the few studies that assessed FDG uptake versus
FMISO uptake in a limited number of patients suffering
from NSCLC, glioblastoma multiforme or breast cancer, no
correlation was found between both variables [22–24].
Based on recent data, it appears that HIF-1 expression
may also be observed in non-hypoxic tumour regions,
suggesting that not only the hypoxic micro-environment but
also non-hypoxic factors such as genetic alterations or
levels of growth factors affect HIF-1 levels and thus also
indirectly affect glucose metabolism [7, 8]. Accordingly, it
cannot be excluded that the existence of a correlation or
lack of correlation between hypoxia and FDG accumulation
is tumour type-dependent.
To conclude, further evaluation of FDG uptake by
various tumour types in relation to intrinsic and bioreduc-
tive markers of hypoxia and response to radiotherapy or
hypoxia-dependent drugs is needed to fully assess its role
as a marker of hypoxia in the clinical setting. In particular,
the relationship between HIF-1 activation and hypoxia in
various human malignancies warrants further study. Whilst
from a biological point of view, FDG uptake by tumour
cells reflects a different aspect of tumour biology when
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compared to the uptake of e.g. FMISO or other hypoxia-
targeting radiopharmaceuticals in those tumours where
HIF-1 activation is mainly hypoxia-driven, the degree of
FDG uptake may be a surrogate marker of hypoxia.
Inversely, in those tumours where HIF-1 activation occurs
mainly independently of hypoxia, specific hypoxia-target-
ing radiopharmaceuticals such as FMISO or 64Cu-ATSM
may be required to non-invasively image tumour hypoxia.
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